Myasthenia gravis is caused by a defect in the action of acetylcholine at neuromuscular junctions. This statement is:

Myasthenia gravis is caused by a defect in the action of acetylcholine at neuromuscular junctions. This statement is:

• A. True
• B. False
• C. Not well understood
• D. Rarely observed

Answer: (A)

Impaired neuromuscular transmission from autoimmune targeting of acetylcholine receptors at the neuromuscular junction is what underlies myasthenia gravis. In this condition, the release of acetylcholine into the synaptic cleft is typically normal, but antibodies bind to postsynaptic acetylcholine receptors, causing receptor destruction and internalization. This reduces the number of functional receptors, so the motor end-plate responds poorly to each acetylcholine release. The end-plate potential often fails to reach the threshold needed to trigger a muscle action potential, especially with sustained use, which explains the fatigable weakness seen in MG. Because the defect is in how acetylcholine acts at the junction, the statement describing MG as caused by a defect in acetylcholine action is true. Clinically, symptoms improve with acetylcholinesterase inhibitors that increase acetylcholine availability in the cleft, and treatment may involve immunosuppressive therapy or thymic interventions in some cases. The other options don’t fit: the mechanism is well understood and centers on receptor impairment, not a lack of understanding or rarity.

Impaired neuromuscular transmission from autoimmune targeting of acetylcholine receptors at the neuromuscular junction is what underlies myasthenia gravis. In this condition, the release of acetylcholine into the synaptic cleft is typically normal, but antibodies bind to postsynaptic acetylcholine receptors, causing receptor destruction and internalization. This reduces the number of functional receptors, so the motor end-plate responds poorly to each acetylcholine release. The end-plate potential often fails to reach the threshold needed to trigger a muscle action potential, especially with sustained use, which explains the fatigable weakness seen in MG.

Because the defect is in how acetylcholine acts at the junction, the statement describing MG as caused by a defect in acetylcholine action is true. Clinically, symptoms improve with acetylcholinesterase inhibitors that increase acetylcholine availability in the cleft, and treatment may involve immunosuppressive therapy or thymic interventions in some cases. The other options don’t fit: the mechanism is well understood and centers on receptor impairment, not a lack of understanding or rarity.